Edwards Lifesciences (EW) stock fell by 2.28% despite receiving upgrades and positive earnings results because of insider selling, which may have created concerns among investors about potential future performance.

Edwards Lifesciences (EW) stock fell by 2

Edwards Lifesciences Corporation's stock (NYSE: EW) increased by 2.52% following its better-than-expected quarterly earnings report, which showed earnings of $0.67 per share and revenue of $1.53 billion, surpassing analysts' estimates and leading to favorable adjustments in price targets by several equity analysts.

Edwards Lifesciences Corporation's stock (NYSE: EW) increased by 2

Edwards Lifesciences (EW) stock rose 2.52% after receiving several upgrades from research analysts, including a rating increase from hold to buy by Wall Street Zen and higher price targets from firms like Wells Fargo and Citigroup, following the company's strong quarterly earnings report that beat analysts' expectations.

Edwards Lifesciences (EW) stock rose 2

Edwards Lifesciences (EW) stock fell by 1.89% despite an increase in target prices from several analysts, likely due to insider selling, which may have raised concerns among investors.

Edwards Lifesciences (EW) stock fell by 1

Edwards Lifesciences (EW) stock fell by 1.89% despite a price target increase to $82.00 from Truist Financial and generally positive quarterly earnings results; the decline may be attributed to a shift in ratings from some analysts, lowering their outlook on the stock from "buy" to "hold."

Edwards Lifesciences (EW) saw a decline of 1.89% in its stock price despite positive upgrades from various analysts, primarily due to insider selling and prevailing market conditions affecting investor sentiment.

Edwards Lifesciences (EW) saw a decline of 1

Edwards Lifesciences (EW) stock fell by 1.89% despite positive earnings and multiple target price increases by analysts, possibly due to negative market sentiment or profit-taking behavior among investors.

Edwards Lifesciences (EW) stock fell by 1.89% despite receiving multiple price target increases from various brokerages, indicating a mixed market reaction possibly influenced by insider selling and market volatility.

Edwards Lifesciences (EW) stock rose 5.5% after reporting stronger-than-expected profits for the latest quarter across all product groups and projecting full-year profits at the high end of its previous forecasts.

Edwards Lifesciences (EW) stock rose 5

Edwards Lifesciences (EW) stock rose 8% after exceeding Wall Street's profit expectations for the latest quarter, driven by strong performance across all its product groups and an optimistic full-year profit forecast.

Edwards Lifesciences (EW) stock rose 8% after exceeding Wall Street's profit expectations for the la

Edwards Lifesciences (EW) stock rose by 5.5% after the company surpassed Wall Street's profit expectations for the latest quarter and indicated strong performance across all product groups while projecting full-year profit at the high end of its previous forecasts.

Edwards Lifesciences (EW) stock rose by 5

Edwards Lifesciences' stock rose 5.54% following a strong second-quarter 2025 earnings report that exceeded revenue and earnings expectations due to significant growth in its heart valve therapies.

Edwards Lifesciences' stock rose 5

Edwards Lifesciences Corporation's stock (NYSE:EW) rose by 5.54% as institutional investors, including J.W. Cole Advisors Inc., significantly increased their holdings in the company, alongside positive analyst ratings and a strong quarterly earnings report that exceeded expectations.

Edwards Lifesciences Corporation's stock (NYSE:EW) rose by 5

Edwards Lifesciences (EW) stock declined by 1.44% likely due to broader market risk aversion and negative sentiment affecting investor confidence in the stock.

Edwards Lifesciences (EW) stock declined by 1

Edwards Lifesciences (EW) stock initially surged after exceeding second-quarter forecasts and raising its outlook, but later experienced a decline of 1.44%. The decrease may be attributed to profit-taking or market fluctuations following the initial excitement from the earnings report.

Edwards Lifesciences (EW) stock initially surged after exceeding second-quarter forecasts and raisin

Edwards Lifesciences (EW) stock rose by 0.8% amidst a broader trend of fund inflows into the healthcare sector, as some investors are starting to look past uncertainties in U.S. drug pricing policies and see long-term growth potential fueled by innovations and aging populations.

Edwards Lifesciences (EW) stock rose by 0

Edwards Lifesciences (EW) stock rose by 0.8% amidst a broader context of cheap valuations in the healthcare sector, driven by investor optimism about potential interest rate cuts that could improve cash flow and reduce R&D costs for quality companies like EW.

Edwards Lifesciences (EW) stock went up by 0.09% due to recent boosts in institutional holdings, positive quarterly earnings exceeding estimates, and favorable analyst ratings enhancing investor confidence.

Edwards Lifesciences (EW) stock went up by 0

Edwards Lifesciences Corporation (NYSE:EW) experienced a 0.87% decline in its stock value, which may be attributed to insider selling activities and mixed ratings from brokerages regarding the stock's future performance.

Edwards Lifesciences Corporation (NYSE:EW) experienced a 0

Edwards Lifesciences (EW) stock was down 0.87% due to a combination of factors, including insider selling by company executives, price target reductions by analysts, and general market dynamics ahead of the upcoming Q2 2025 earnings announcement.

Edwards Lifesciences (EW) stock was down 0

Edwards Lifesciences Corporation (EW) stock fell by 0.87% following a reduction of its stake by Ballentine Partners LLC and ongoing insider selling, despite positive earnings results and modifications in holdings by other institutional investors.

Edwards Lifesciences Corporation (EW) stock fell by 0

Edwards Lifesciences Corporation (EW) stock decreased by 0.87%, partly due to recent insider selling by executives and a mix of ratings upgrades and downgrades from various analysts, reflecting some uncertainty among investors.

Edwards Lifesciences Corporation (EW) stock decreased by 0

Edwards Lifesciences (EW) stock rose by 2.09% likely due to analysts upgrading their target prices and the company reporting better-than-expected earnings and revenue for the last quarter.

Edwards Lifesciences (EW) stock rose by 2

Edwards Lifesciences (EW) stock increased by 1.05% due to positive earnings results that exceeded analysts' expectations, as the company reported a rise in revenue and earnings per share, indicating strong business performance in the medical research sector.

Edwards Lifesciences (EW) stock increased by 1

The article discusses the positive movement of Abbott Laboratories' stock, which was supported by a favorable decision from the Centers for Medicare & Medicaid Services regarding transcatheter edge-to-edge repair for the tricuspid valve, likely benefiting Edwards Lifesciences as well due to similarities in their technologies. 

Edwards Lifesciences' stock may have increased by 1.05% due to the overall positive sentiment surrounding advancements and regulatory support in procedures related to heart valve replacements and interventional cardiology, which are central to its business.

The article discusses the positive movement of Abbott Laboratories' stock, which was supported by a 

Edwards Lifesciences Corporation's stock (NYSE:EW) experienced a slight decline of -0.13%, attributed to a mix of institutional investor activity, analyst rating changes—including reductions in price targets—and insider selling, which may have influenced investor sentiment.

Edwards Lifesciences Corporation's stock (NYSE:EW) experienced a slight decline of -0

Edwards Lifesciences Corporation (NYSE:EW) stock fell by 0.3% amid an average recommendation of "Hold" from analysts and recent downgrades from some firms, reflecting cautious sentiment in the market. The stock decline is attributed to negative analyst ratings and insider sales, which may indicate a lack of confidence in the stock's short-term performance.

Edwards Lifesciences Corporation (NYSE:EW) stock fell by 0

Edwards Lifesciences (EW) stock recently experienced a decline of 1.32%, potentially due to insider selling by executives and mixed analyst ratings that may have affected investor confidence.

Edwards Lifesciences (EW) stock recently experienced a decline of 1

Edwards Lifesciences (EW) stock declined by 1.32% as Envestnet Portfolio Solutions significantly reduced its holdings in the company by 90.7%, indicating a lack of investor confidence which may have contributed to the stock's downturn.

Edwards Lifesciences (EW) stock was down 0.0% as Bessemer Group Inc. reduced its stake by 47.8%, indicating potential concerns among institutional investors about the company's future performance.

Edwards Lifesciences' (EW) stock was down 0.0% last night despite increased institutional investments, insider sales, and mixed ratings from analysts, indicating possible volatility in investor sentiment. The reasons for the stock's stagnation include recent insider selling by executives, revised price targets from research analysts, and maintaining an overall "hold" rating from most analysts, reflecting cautious market support.

Edwards Lifesciences' (EW) stock was down 0

Edwards Lifesciences (EW) stock rose 1.48% as institutional investors, including Norges Bank and Vanguard Group, increased their holdings, reflecting positive sentiment towards the company's recent financial performance, including earnings that exceeded analyst estimates.

Edwards Lifesciences (EW) stock rose 1

Edwards Lifesciences (EW) stock rose 1.48% amidst a backdrop of changes in institutional investment and positive earnings results; the increase can be attributed to recent institutional buying activity and analyst upgrades that reflect confidence in the company's growth prospects.

Edwards Lifesciences Corporation's (NYSE:EW) stock rose 0.7%, attributed to significant increases in institutional investments, including a notable 339.2% increase by Kentucky Retirement Systems Insurance Trust Fund in the first quarter, alongside positive quarterly earnings that beat analyst expectations.

Edwards Lifesciences Corporation's (NYSE:EW) stock rose 0

Edwards Lifesciences (EW) stock rose by 0.97% due to significant increases in institutional holdings, positive earnings performance exceeding analyst expectations, and favorable adjustments to price targets by several analysts.

Edwards Lifesciences (EW) stock rose 0.56% likely due to positive analyst ratings and increased institutional interest, with several major investors boosting their stakes and raising target prices following the company's strong earnings report, which exceeded analysts' expectations.

Edwards Lifesciences (EW) stock rose 0

Edwards Lifesciences (EW) stock declined by 0.73% partly due to insider selling by company executives, which may have raised concerns among investors about the stock's current valuation and future prospects.

Edwards Lifesciences (EW) stock declined by 0

Edwards Lifesciences Co. (EW) saw a 1.5% decline in its stock price, influenced by recent insider selling and mixed analyst ratings, with some upgrades overshadowed by downgrades and uncertain investor sentiment following personnel transactions.

Edwards Lifesciences Co

Edwards Lifesciences (EW) stock fell by 0.15% despite raised earnings estimates for Q3 2025, likely due to mixed analyst ratings, insider selling, and profit-taking among investors.

Edwards Lifesciences (EW) stock fell by 0

Edwards Lifesciences (EW) stock rose 0.58% after Boston Scientific announced it would cease selling its competing heart-valve replacement systems, benefiting Edwards and other companies in the sector.

Edwards Lifesciences (EW) stock rose 1.64% following significant increases in institutional investor holdings, positive earnings results that beat analysts' expectations, and optimistic upgrades in price targets from several research analysts.

Edwards Lifesciences (EW) stock increased by 0.27% due in part to positive quarterly earnings that surpassed analysts' expectations, strong revenue growth, and favorable analyst upgrades regarding its stock price targets.

Edwards Lifesciences (EW) stock increased by 0

Edwards Lifesciences (EW) stock fell by -1.72% likely due to the impact of revised tariff-related guidance that rendered previous forecasts uncertain, amidst a backdrop of generally stable core MedTech fundamentals but high sensitivity to stock performance in the sector.

Edwards Lifesciences (EW) stock fell by -1

Edwards Lifesciences (EW) stock rose by 1.46% despite a recent downgrade to "hold" from "buy" by StockNews.com, as well as several mixed ratings from other analysts, following a quarterly earnings report that exceeded expectations and showed a year-over-year revenue increase of 6.2%.

Edwards Lifesciences (EW) stock rose by 1

Edwards Lifesciences (EW) stock decreased by 0.41%, likely due to overall market fluctuations or investor sentiment, despite a recent monthly increase of 3.30% and a notable annual decline of 11.57%.

Edwards Lifesciences (EW) stock decreased by 0

Edwards Lifesciences (NYSE:EW) stock rose by 0.98% following a report that showed the company exceeded earnings expectations for the previous quarter, generating positive investor sentiment despite some downward adjustment in future earnings estimates by analysts.

Edwards Lifesciences (NYSE:EW) stock rose by 0

Edwards Lifesciences (EW) stock declined by 0.66% despite a price target increase from Canaccord Genuity and mostly neutral to positive ratings from other analysts, potentially due to recent insider selling and mixed analyst sentiment regarding its future performance.

EW

Latest News & Analysis